» Articles » PMID: 22715468

Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3+ Regulatory T Cell Function Through Shared and Isoform-specific Mechanisms

Overview
Journal Sci Signal
Date 2012 Jun 21
PMID 22715468
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic inhibition of the histone deacetylases HDAC6, HDAC9, or sirtuin-1 (Sirt1) augments the suppressive functions of regulatory T cells (T(regs)) that contain the transcription factor Foxp3 (Forkhead box P3) and is useful in organ transplant patients or patients with autoimmune diseases. However, it is unclear whether distinct mechanisms are involved for each HDAC or whether combined inhibition of HDACs would be more effective. We compared the suppressive functions of T(regs) from wild-type C57BL/6 mice with those from mice with either complete or cell-specific deletion of various HDACs, as well as with those of T(regs) treated with isoform-selective HDAC inhibitors. The improvement of T(reg) suppressive function mediated by inhibition of HDAC6, but not Sirt1, required an intact heat shock response. Although HDAC6, HDAC9, and Sirt1 all deacetylated Foxp3, each protein had different effects on transcription factors that control expression of the gene encoding Foxp3. For example, loss of HDAC9, but not other HDACs, was associated with stabilization of the acetylated form of signal transducer and activator of transcription 5 (STAT5) and promoted its transcriptional activity. Thus, targeting different HDACs increased T(reg) function through multiple and additive mechanisms, which suggests the therapeutic potential for using combinations of HDAC inhibitors in the management of autoimmunity and organ transplantation.

Citing Articles

The epigenetic hallmarks of immune cells in cancer.

Ji Y, Xiao C, Fan T, Deng Z, Wang D, Cai W Mol Cancer. 2025; 24(1):66.

PMID: 40038722 PMC: 11881328. DOI: 10.1186/s12943-025-02255-4.


HSP90 multi-functionality in cancer.

Albakova Z Front Immunol. 2024; 15:1436973.

PMID: 39148727 PMC: 11324539. DOI: 10.3389/fimmu.2024.1436973.


A novel insight into neurological disorders through HDAC6 protein-protein interactions.

Bahram Sangani N, Koetsier J, Melius J, Kutmon M, Ehrhart F, Evelo C Sci Rep. 2024; 14(1):14666.

PMID: 38918466 PMC: 11199618. DOI: 10.1038/s41598-024-65094-1.


Biomolecular Actions by Intestinal Endotoxemia in Metabolic Syndrome.

Charitos I, Aliani M, Tondo P, Venneri M, Castellana G, Scioscia G Int J Mol Sci. 2024; 25(5).

PMID: 38474087 PMC: 10931779. DOI: 10.3390/ijms25052841.


Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?.

Liu J, Zhang B, Zhang G, Shang D Front Immunol. 2024; 15:1345838.

PMID: 38449875 PMC: 10915070. DOI: 10.3389/fimmu.2024.1345838.


References
1.
Feuerer M, Hill J, Mathis D, Benoist C . Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol. 2009; 10(7):689-95. DOI: 10.1038/ni.1760. View

2.
de Zoeten E, Wang L, Sai H, Dillmann W, Hancock W . Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 2009; 138(2):583-94. PMC: 3369426. DOI: 10.1053/j.gastro.2009.10.037. View

3.
Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

4.
Zorn E, Nelson E, Mohseni M, Porcheray F, Kim H, Litsa D . IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006; 108(5):1571-9. PMC: 1895505. DOI: 10.1182/blood-2006-02-004747. View

5.
McMurchy A, Bushell A, Levings M, Wood K . Moving to tolerance: clinical application of T regulatory cells. Semin Immunol. 2011; 23(4):304-13. PMC: 3836227. DOI: 10.1016/j.smim.2011.04.001. View